Enanta Non Currrent Assets Other vs Common Stock Shares Outstanding Analysis

ENTA Stock

USD 9.34 0.03 0.32%

Enanta Pharmaceuticals financial indicator trend analysis is much more than just examining Enanta Pharmaceuticals latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Enanta Pharmaceuticals is a good investment. Please check the relationship between Enanta Pharmaceuticals Non Currrent Assets Other and its Common Stock Shares Outstanding accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Enanta Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For information on how to trade Enanta Stock refer to our How to Trade Enanta Stock guide.

Non Currrent Assets Other vs Common Stock Shares Outstanding

Non Currrent Assets Other vs Common Stock Shares Outstanding Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Enanta Pharmaceuticals Non Currrent Assets Other account and Common Stock Shares Outstanding. At this time, the significance of the direction appears to have almost no relationship.

The correlation between Enanta Pharmaceuticals' Non Currrent Assets Other and Common Stock Shares Outstanding is 0.17. Overlapping area represents the amount of variation of Non Currrent Assets Other that can explain the historical movement of Common Stock Shares Outstanding in the same time period over historical financial statements of Enanta Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Enanta Pharmaceuticals' Non Currrent Assets Other and Common Stock Shares Outstanding is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Non Currrent Assets Other of Enanta Pharmaceuticals are associated (or correlated) with its Common Stock Shares Outstanding. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Common Stock Shares Outstanding has no effect on the direction of Non Currrent Assets Other i.e., Enanta Pharmaceuticals' Non Currrent Assets Other and Common Stock Shares Outstanding go up and down completely randomly.

Correlation Coefficient

0.17

Relationship Direction	Positive
Relationship Strength	Insignificant

View All Relationships

Non Currrent Assets Other

Assets that are not physical or tangible, expected to provide value for more than one year, and not easily converted into cash, such as long-term investments or patents.

Common Stock Shares Outstanding

The total number of shares of a company's common stock that are currently owned by all its shareholders.

Most indicators from Enanta Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Enanta Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Enanta Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For information on how to trade Enanta Stock refer to our How to Trade Enanta Stock guide.At present, Enanta Pharmaceuticals' Selling General Administrative is projected to increase significantly based on the last few years of reporting. The current year's Sales General And Administrative To Revenue is expected to grow to 0.63, whereas Tax Provision is forecasted to decline to about 2.4 M.

	2021	2022	2023	2024 (projected)
Gross Profit	83.2M	79.2M	91.1M	104.6M
Total Revenue	86.2M	79.2M	91.1M	104.9M

Gross Profit Total Revenue

Enanta Pharmaceuticals fundamental ratios Correlations

	Common Stock Shares Outstanding	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Short Term Investments	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Preferred Stock Total Equity	Total Current Assets	Common Stock
Common Stock Shares Outstanding		0.79	0.4	0.47	0.63	-0.44	0.51	-0.6	0.21	0.53	0.62	0.6	0.17	0.43	0.73	0.61	0.84	0.73	0.21	0.49	0.85	0.28	0.44	-0.73	0.75	0.84
Total Assets	0.79		0.55	0.65	0.85	-0.41	0.63	-0.8	0.26	0.8	0.8	0.59	0.33	0.38	0.97	0.81	0.78	0.97	0.16	0.63	0.91	0.28	0.54	-0.67	0.98	0.78
Other Current Liab	0.4	0.55		0.98	0.18	-0.66	0.94	-0.45	-0.6	0.31	0.8	0.11	0.87	0.07	0.6	0.43	0.4	0.57	0.84	0.21	0.62	0.91	0.93	-0.29	0.59	0.42
Total Current Liabilities	0.47	0.65	0.98		0.31	-0.71	0.95	-0.55	-0.5	0.46	0.87	0.25	0.84	0.07	0.67	0.5	0.47	0.64	0.77	0.31	0.7	0.85	0.93	-0.35	0.66	0.49
Total Stockholder Equity	0.63	0.85	0.18	0.31		-0.15	0.31	-0.72	0.62	0.81	0.58	0.72	0.0	0.46	0.76	0.71	0.72	0.78	-0.29	0.6	0.7	-0.16	0.2	-0.74	0.79	0.72
Other Liab	-0.44	-0.41	-0.66	-0.71	-0.15		-0.76	0.21	0.5	-0.34	-0.53	-0.28	-0.66	0.35	-0.39	-0.26	-0.46	-0.36	-0.54	-0.42	-0.63	-0.6	-0.76	0.36	-0.39	-0.47
Property Plant And Equipment Net	0.51	0.63	0.94	0.95	0.31	-0.76		-0.44	-0.51	0.39	0.81	0.17	0.91	0.09	0.67	0.48	0.5	0.66	0.73	0.36	0.74	0.82	0.99	-0.38	0.67	0.52
Net Debt	-0.6	-0.8	-0.45	-0.55	-0.72	0.21	-0.44		-0.29	-0.6	-0.88	-0.46	-0.16	-0.31	-0.79	-0.55	-0.55	-0.74	-0.16	-0.58	-0.64	-0.26	-0.35	0.51	-0.79	-0.56
Retained Earnings	0.21	0.26	-0.6	-0.5	0.62	0.5	-0.51	-0.29		0.39	-0.13	0.46	-0.72	0.38	0.17	0.26	0.17	0.2	-0.78	0.28	0.01	-0.75	-0.6	-0.25	0.19	0.15
Accounts Payable	0.53	0.8	0.31	0.46	0.81	-0.34	0.39	-0.6	0.39		0.56	0.73	0.16	0.15	0.68	0.82	0.53	0.67	-0.08	0.51	0.68	0.04	0.3	-0.47	0.73	0.53
Cash	0.62	0.8	0.8	0.87	0.58	-0.53	0.81	-0.88	-0.13	0.56		0.35	0.59	0.2	0.83	0.57	0.59	0.78	0.52	0.55	0.76	0.63	0.74	-0.49	0.82	0.6
Non Current Assets Total	0.6	0.59	0.11	0.25	0.72	-0.28	0.17	-0.46	0.46	0.73	0.35		-0.08	0.37	0.4	0.5	0.59	0.4	-0.24	0.32	0.57	-0.14	0.09	-0.6	0.44	0.58
Non Currrent Assets Other	0.17	0.33	0.87	0.84	0.0	-0.66	0.91	-0.16	-0.72	0.16	0.59	-0.08		-0.02	0.39	0.3	0.18	0.37	0.75	0.09	0.48	0.8	0.95	-0.07	0.39	0.2
Other Assets	0.43	0.38	0.07	0.07	0.46	0.35	0.09	-0.31	0.38	0.15	0.2	0.37	-0.02		0.35	0.29	0.34	0.38	-0.13	-0.13	0.28	-0.09	0.05	-0.38	0.34	0.34
Cash And Short Term Investments	0.73	0.97	0.6	0.67	0.76	-0.39	0.67	-0.79	0.17	0.68	0.83	0.4	0.39	0.35		0.72	0.73	0.99	0.26	0.64	0.88	0.36	0.58	-0.61	0.99	0.74
Net Receivables	0.61	0.81	0.43	0.5	0.71	-0.26	0.48	-0.55	0.26	0.82	0.57	0.5	0.3	0.29	0.72		0.55	0.73	0.09	0.28	0.72	0.19	0.42	-0.45	0.79	0.55
Common Stock Total Equity	0.84	0.78	0.4	0.47	0.72	-0.46	0.5	-0.55	0.17	0.53	0.59	0.59	0.18	0.34	0.73	0.55		0.74	0.04	0.48	0.86	0.14	0.44	-0.96	0.74	1.0
Short Term Investments	0.73	0.97	0.57	0.64	0.78	-0.36	0.66	-0.74	0.2	0.67	0.78	0.4	0.37	0.38	0.99	0.73	0.74		0.23	0.63	0.87	0.33	0.57	-0.63	0.99	0.74
Non Current Liabilities Total	0.21	0.16	0.84	0.77	-0.29	-0.54	0.73	-0.16	-0.78	-0.08	0.52	-0.24	0.75	-0.13	0.26	0.09	0.04	0.23		0.01	0.25	0.99	0.77	0.11	0.23	0.06
Other Current Assets	0.49	0.63	0.21	0.31	0.6	-0.42	0.36	-0.58	0.28	0.51	0.55	0.32	0.09	-0.13	0.64	0.28	0.48	0.63	0.01		0.56	0.08	0.27	-0.42	0.63	0.48
Other Stockholder Equity	0.85	0.91	0.62	0.7	0.7	-0.63	0.74	-0.64	0.01	0.68	0.76	0.57	0.48	0.28	0.88	0.72	0.86	0.87	0.25	0.56		0.37	0.68	-0.74	0.89	0.87
Total Liab	0.28	0.28	0.91	0.85	-0.16	-0.6	0.82	-0.26	-0.75	0.04	0.63	-0.14	0.8	-0.09	0.36	0.19	0.14	0.33	0.99	0.08	0.37		0.84	0.01	0.35	0.16
Property Plant And Equipment Gross	0.44	0.54	0.93	0.93	0.2	-0.76	0.99	-0.35	-0.6	0.3	0.74	0.09	0.95	0.05	0.58	0.42	0.44	0.57	0.77	0.27	0.68	0.84		-0.32	0.58	0.46
Preferred Stock Total Equity	-0.73	-0.67	-0.29	-0.35	-0.74	0.36	-0.38	0.51	-0.25	-0.47	-0.49	-0.6	-0.07	-0.38	-0.61	-0.45	-0.96	-0.63	0.11	-0.42	-0.74	0.01	-0.32		-0.62	-0.96
Total Current Assets	0.75	0.98	0.59	0.66	0.79	-0.39	0.67	-0.79	0.19	0.73	0.82	0.44	0.39	0.34	0.99	0.79	0.74	0.99	0.23	0.63	0.89	0.35	0.58	-0.62		0.74
Common Stock	0.84	0.78	0.42	0.49	0.72	-0.47	0.52	-0.56	0.15	0.53	0.6	0.58	0.2	0.34	0.74	0.55	1.0	0.74	0.06	0.48	0.87	0.16	0.46	-0.96	0.74

Click cells to compare fundamentals

Enanta Pharmaceuticals Account Relationship Matchups

Enanta Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Common Stock Shares Outstanding	19.9M	20.2M	20.6M	21.0M	24.1M	18.0M
Total Assets	486.1M	438.8M	375.4M	462.3M	531.6M	327.6M
Other Current Liab	9.9M	18.2M	18.0M	53.4M	61.4M	64.5M
Total Current Liabilities	24.2M	36.2M	29.8M	62.8M	72.2M	75.8M
Total Stockholder Equity	455.6M	399.4M	321.3M	216.7M	249.2M	273.1M
Other Liab	2.9M	1.1M	558K	454K	408.6K	388.2K
Property Plant And Equipment Net	15.6M	10.7M	29.7M	34.7M	39.9M	41.9M
Net Debt	(79.0M)	(51.9M)	(18.7M)	(58.9M)	(53.0M)	(55.6M)
Retained Earnings	127.6M	48.6M	(73.2M)	(207.0M)	(238.0M)	(226.1M)
Accounts Payable	5.7M	9.5M	6M	4.1M	4.7M	4.3M
Cash	87.1M	57.2M	44.0M	85.4M	98.2M	103.1M
Non Current Assets Total	49.3M	119.8M	63.7M	39.5M	45.4M	56.9M
Other Assets	12.0M	1.0M	700K	4.7M	5.4M	5.6M
Cash And Short Term Investments	386.6M	244.0M	249.2M	369.9M	425.4M	231.2M
Net Receivables	23.5M	60.8M	49.0M	39.6M	45.6M	28.8M
Common Stock Total Equity	197K	201K	202K	208K	239.2K	183.8K
Short Term Investments	299.5M	186.8M	205.2M	284.5M	327.2M	184.7M
Liabilities And Stockholders Equity	486.1M	438.8M	375.4M	462.3M	531.6M	327.6M
Non Current Liabilities Total	6.4M	3.2M	24.2M	182.8M	210.2M	220.7M
Other Current Assets	40.4M	14.2M	13.4M	13.3M	15.3M	11.8M
Other Stockholder Equity	327.0M	351.0M	398.0M	424.7M	488.4M	264.1M
Total Liab	30.6M	39.4M	54.1M	245.5M	282.4M	296.5M
Property Plant And Equipment Gross	15.6M	10.7M	51.6M	58.5M	67.2M	70.6M
Total Current Assets	436.8M	319.0M	311.7M	422.8M	486.2M	270.6M
Accumulated Other Comprehensive Income	844K	(382K)	(3.7M)	(1.2M)	(1.1M)	(1.0M)
Common Stock	201K	202K	208K	211K	242.7K	187.5K
Property Plant Equipment	10.9M	8.6M	10.7M	29.7M	34.2M	35.9M
Short Long Term Debt Total	8.1M	5.3M	25.3M	26.5M	30.5M	32.0M
Net Tangible Assets	462.5M	455.6M	399.4M	321.3M	369.5M	365.3M
Capital Surpluse	298.4M	327.0M	351.0M	398.0M	457.7M	317.9M
Long Term Investments	16.4M	65.0M	32.6M	108.4M	29.3M	0.0
Non Current Liabilities Other	6.4M	558K	454K	160.1M	184.1M	193.3M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

When determining whether Enanta Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Enanta Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Enanta Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Enanta Pharmaceuticals Stock:

How To Invest In Enanta

Details

Is Enanta Stock a good investment?

Details

What is Enanta Pharmaceuticals' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Enanta Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For information on how to trade Enanta Stock refer to our How to Trade Enanta Stock guide.

You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Enanta Pharmaceuticals. If investors know Enanta will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Enanta Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.66)

Earnings Share

(5.45)

Revenue Per Share

3.407

Quarterly Revenue Growth

(0.05)

Return On Assets

(0.17)

The market value of Enanta Pharmaceuticals is measured differently than its book value, which is the value of Enanta that is recorded on the company's balance sheet. Investors also form their own opinion of Enanta Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Enanta Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Enanta Pharmaceuticals' market value can be influenced by many factors that don't directly affect Enanta Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Enanta Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Enanta Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Enanta Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Enanta Non Currrent Assets Other vs Common Stock Shares Outstanding Analysis

Non Currrent Assets Other vs Common Stock Shares Outstanding

Non Currrent Assets Other vs Common Stock Shares Outstanding Correlation Analysis

Correlation Coefficient

Non Currrent Assets Other

Common Stock Shares Outstanding

Enanta Pharmaceuticals fundamental ratios Correlations

Enanta Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Enanta Pharmaceuticals fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Common Stock	+ 1.0	Common Stock Total Equity
Property Plant And Equipment Gross	+ 0.99	Property Plant And Equipment Net
Short Term Investments	+ 0.99	Cash And Short Term Investments
Total Current Assets	+ 0.99	Cash And Short Term Investments
Total Current Assets	+ 0.99	Short Term Investments
Total Liab	+ 0.99	Non Current Liabilities Total

Common Stock	- 0.96	Preferred Stock Total Equity
Preferred Stock Total Equity	- 0.96	Common Stock Total Equity
Cash	- 0.88	Net Debt
Net Debt	- 0.8	Total Assets
Total Current Assets	- 0.79	Net Debt
Cash And Short Term Investments	- 0.79	Net Debt